Breakthrough Vaccine to Treat Chemo-Resistant Ovarian Cancer
2007年3月8日 - 9:00PM
PRニュース・ワイアー (英語)
Cancer Treatment Centers of America plans cutting-edge
patient-specific vaccine therapy CHICAGO, March 8 /PRNewswire/ --
Cancer Treatment Centers of America announced today its plans to
launch a new cancer vaccine therapy that expands treatment options
for thousands of women with advanced stage ovarian cancer. This
innovative treatment will be offered by Cancer Treatment Centers of
America and developed by AVAX Technologies, Inc. (OTC:AVXT)
(BULLETIN BOARD: AVXT) . "Cancer Treatment Centers of America's
number one priority is to help our patients win the battle against
cancer," said Dr. Edgar Staren, Chief Medical Officer of Cancer
Treatment Centers of America. "This vaccine therapy represents a
promising new chapter in the fight against this devastating disease
and brings hope to women everywhere." The breakthrough treatment
method uses the patient's own tumor tissues to create a
patient-specific vaccine and is combined with chemotherapy
delivered directly into the abdominal cavity. Ovarian cancer, one
of the hardest cancers to detect in the early stages, is a very
complex disease that is often resistant to chemotherapy. Cancer
Treatment Centers of America will offer this new treatment to
patients whose cancer has recurred after chemotherapy. "To win the
fight against cancer, it is absolutely vital we do everything we
can to make innovative new treatments like this available to
patients as soon as possible," said Dr. Staren. "It's inconceivable
that treatments like these -- that give hope to patients -- are
often left on the laboratory bench, while cancer patients are told
there is nothing more that can be done for them." Cancer Treatment
Centers of America expects to start treating patients this summer.
This promising vaccine technology hopes to eventually be available
to treat other forms of cancer including colorectal and lung cancer
patients, as well as patients with malignant melanomas. About
Cancer Treatment Centers of America Founded in 1988, Cancer
Treatment Centers of America (CTCA) provides a comprehensive,
patient-centered treatment model that fully integrates traditional,
state-of-the-art medical treatments with scientifically-supported
complementary and alternative therapies such as nutrition,
naturopathy, psychological counseling, physical therapy and
spiritual support to meet the special, whole-person needs of
advanced-stage cancer patients. With a network of cancer treatment
hospitals and community oncology programs in Illinois, Oklahoma,
Pennsylvania and Washington, CTCA encourages patients and their
families to participate in treatment decisions with its Patient
Empowerment MedicineSM model. AVAX Technologies, Inc. AVAX
Technologies, Inc. is a biotechnology company with operations in
the United States and Europe. The Company is engaged in the
research, clinical and commercial development of biological
products and cancer therapeutics. AVAX's AC Vaccine platform is a
therapeutic treatment for cancer. In addition, the Company performs
contract-manufacturing services for biological products to other
pharmaceutical and biotechnology companies. DATASOURCE: Cancer
Treatment Centers of America CONTACT: Lisa Trafficanta,
+1-312-755-3541, cell, +1-708-989-4944, or Chris Hamrick,
+1-847-342-7458, cell, +1-847-528-8185, for Cancer Treatment
Centers of America
Copyright